Therapeutic vaccines for treating herpes simplex virus type-2 infections
OwnerKejian YANG, Dennis L. GUBERSKIinventors
Life of this patent
Estimating the term…
Abstract
The invention provides methods and kits for inducing a therapeutic immunity in animals (e.g. mammals) against viral antigens, including herpes-simplex virus type 2. In particular, the invention provides a method of treating animals with an established HSV-2 infection by administering a therapeutic vaccine comprising a priming dose of a nucleic acid encoding an HSV-2 antigen, an initial or first boosting dose comprising the protein form of the antigen encapsulated in liposomes, and one or more subsequent boosting doses comprising both the nucleic acid encoding the HSV-2 antigen and the liposomal-encapsulated protein antigen.
Claims26
A method for treating an HSV-2 infection in a mammal comprising administering to the mammal:
- (a) a priming preparation comprising a vector encoding an HSV-2 antigen under the control of a promoter;
- (b) a first boosting preparation comprising the HSV-2 antigen encapsulated in liposomes;
- and
- (c) a second boosting preparation comprising the vector encoding the HSV-2 antigen and the HSV-2 antigen encapsulated in liposomes,
- wherein the vector is administered intramuscularly and the liposomal-encapsulated antigen is administered intranasally.
Dependencies are inferred from the claim text.